Umckaloabo
•Last Updated: September 28 2022
Pelargonium sidoides, also known as African geranium, is a plant-derived pharmaceutical used to treat acute bronchitis. It may also act as an immune system booster, and alleviate symptoms of the common cold and herpes.
Umckaloabo is most often used for
Last Updated: September 28 2022
Pelargonium sidoides, commonly known as African geranium, is a medicinal herb. It is also sold under the brand names Kaloban and Umckaloabo as a plant-derived pharmaceutical.
Pelargonium sidoides is very effective for treating acute bronchitis. It increases the body’s natural healing rate. Studies have found that 40-60% of patients suffering from acute bronchitis fully resolve their symptoms within a week of Pelargonium sidoides supplementation. Some people reported experiencing benefits after just two to three days. People that are not cured after a week still experience benefits from Pelargonium sidoides supplementation, since it can treat the symptoms associated with bronchitis, including headache, fever, fatigue, cough, chest pain while coughing, sputum in the lungs, rhonchi, and nasal dripping.
Preliminary evidence suggests Pelargonium sidoides can reduce the duration of the common cold, while treating symptoms. It may also provide benefits for people suffering from lung disorders, by alleviating flare-ups in symptoms.
Pelargonium sidoides has anti-infective properties. It prevents bacteria from adhering to cells, helps fight viruses and stimulates the immune system to hunt down invaders.
Pelargonium sidoides may be able to fight Helicobacter pylori infection, which is the stomach bacteria that causes stomach ulcers. Pelargonium sidoides may also reduce the replication of the herpes simplex virus.
Note that Umckaloabo is also known as:
- African Geranium
- South African Geranium
- Kaloban EPs7630
- EPs 7630
- Umckaloabo
- Rabas
- Pelargonium Sidoides
Umckaloabo should not be confused with:
- Pelargonidin (Isolated anthocyanin)
- Ginkgo biloba (EGb-761)
To supplement Pelargonium sidoides, take the patented extract EPS7630, which is an 11% ethanolic root extract.
The extract is concentrated to 1:8-10, so there is some variability with the recommended dosages. To supplement the extract, take 4.5mL of the tincture (30 drops) or 30 mg of the capsules. Dosages vary by age:
• 10 drops (1.5mL) or 10mg of EPs7630 is taken thrice daily before meals for those under six years of age • 20 drops (3.0mL) or 20mg of EPs7630 is taken thrice daily before meals for those between six and twelve • 30 drops (4.5mL) or 30mg of EPs7630 is taken thrice daily before meals for those above twelve years of age
While the vast majority of studies have used EPs7630 specifically, any hydroalcoholic (water and ethanol) extraction equal to 800mg of the plant can be used as an alternative.
What works and what doesn't?
Unlock the full potential of Examine
1.^Moyo M, Aremu AO, Gruz J, Subrtová M, Szüčová L, Doležal K, Van Staden JConservation strategy for Pelargonium sidoides DC: Phenolic profile and pharmacological activity of acclimatized plants derived from tissue cultureJ Ethnopharmacol.(2013 Sep 16)
2.^van Wyk BEA broad review of commercially important southern African medicinal plantsJ Ethnopharmacol.(2008 Oct 28)
3.^Kolodziej HFascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine UmckaloaboPhytomedicine.(2007)
4.^Colling J, Groenewald JH, Makunga NPGenetic alterations for increased coumarin production lead to metabolic changes in the medicinally important Pelargonium sidoides DC (Geraniaceae)Metab Eng.(2010 Nov)
5.^Brendler T, van Wyk BEA historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae)J Ethnopharmacol.(2008 Oct 28)
6.^Unusual coumarin patterns of Pelargonium species forming the origin of the traditional herbal medicine umckaloabo.()
7.^Tabali M, Ostermann T, Jeschke E, Witt CM, Matthes HAdverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugsJ Manag Care Pharm.(2012 Jul-Aug)
9.^The leaves of Pelargonium sidoides may substitute for its roots in the treatment of bacterial infections.()
10.^Kolodziej H, Kayser O, Radtke OA, Kiderlen AF, Koch EPharmacological profile of extracts of Pelargonium sidoides and their constituentsPhytomedicine.(2003)
11.^Kayser O, Kolodziej HAntibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniformePlanta Med.(1997 Dec)
13.^Hauer H, Germer S, Elsässer J, Ritter TBenzopyranones and their sulfate esters from Pelargonium sidoidesPlanta Med.(2010 Mar)
14.^Theisen LL, Muller CPEPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivoAntiviral Res.(2012 May)
15.^Janecki A, Kolodziej HAnti-adhesive activities of flavan-3-ols and proanthocyanidins in the interaction of group A-streptococci and human epithelial cellsMolecules.(2010 Oct 15)
16.^Foo LY, Lu Y, Molan AL, Woodfield DR, McNabb WCThe phenols and prodelphinidins of white clover flowersPhytochemistry.(2000 Jun)
18.^Schötz K, Nöldner MMass spectroscopic characterisation of oligomeric proanthocyanidins derived from an extract of Pelargonium sidoides roots (EPs 7630) and pharmacological screening in CNS modelsPhytomedicine.(2007)
19.^Phytochemical distinction between Pelargonium sidoides and Pelargonium reniforme — A quality control perspective.()
20.^Matthys H, Eisebitt R, Seith B, Heger MEfficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trialPhytomedicine.(2003)
21.^Matthys H, Pliskevich DA, Bondarchuk OM, Malek FA, Tribanek M, Kieser MRandomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPDRespir Med.(2013 May)
22.^Matthys H, Lizogub VG, Malek FA, Kieser MEfficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoidesCurr Med Res Opin.(2010 Jun)
23.^Schoetz K, Erdelmeier C, Germer S, Hauer HA detailed view on the constituents of EPs 7630Planta Med.(2008 May)
24.^Franco L, de Oliveira BHDetermination of umckalin in commercial tincture and phytopreparations containing Pelargonium sidoides by HPLC: comparison of sample preparation proceduresTalanta.(2010 Jun 15)
25.^Luna LA Jr, Bachi AL, Novaes e Brito RR, Eid RG, Suguri VM, Oliveira PW, Gregorio LC, Vaisberg MImmune responses induced by Pelargonium sidoides extract in serum and nasal mucosa of athletes after exhaustive exercise: modulation of secretory IgA, IL-6 and IL-15Phytomedicine.(2011 Feb 15)
26.^Koch E, Biber ATreatment of rats with the Pelargonium sidoides extract EPs 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarinPhytomedicine.(2007)
27.^Brekhman II, Dardymov IVNew substances of plant origin which increase nonspecific resistanceAnnu Rev Pharmacol.(1969)
28.^Panossian A, Wikman G, Wagner HPlant adaptogens. III. Earlier and more recent aspects and concepts on their mode of actionPhytomedicine.(1999 Oct)
30.^Asea A, Kaur P, Panossian A, Wikman KGEvaluation of molecular chaperons Hsp72 and neuropeptide Y as characteristic markers of adaptogenic activity of plant extractsPhytomedicine.(2013 Aug 3)
31.^Patiroglu T, Tunc A, Eke Gungor H, Unal EThe efficacy of Pelargonium sidoides in the treatment of upper respiratory tract infections in children with transient hypogammaglobulinemia of infancyPhytomedicine.(2012 Aug 15)
32.^Tahan F, Yaman MCan the Pelargonium sidoides root extract EPs® 7630 prevent asthma attacks during viral infections of the upper respiratory tract in childrenPhytomedicine.(2013 Jan 15)
33.^Matthys H, Heger MTreatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre studyCurr Med Res Opin.(2007 Feb)
34.^Matthys H, Funk PEPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trialPlanta Med.(2008 May)
35.^Matthys H, Kamin W, Funk P, Heger MPelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and childrenPhytomedicine.(2007)
36.^Chuchalin AG, Berman B, Lehmacher WTreatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trialExplore (NY).(2005 Nov)
37.^Matthys H, Heger MEPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitisPhytomedicine.(2007)
38.^Lizogub VG, Riley DS, Heger MEfficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trialExplore (NY).(2007 Nov-Dec)
39.^Kamin W, Maydannik VG, Malek FA, Kieser MEfficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitisActa Paediatr.(2010 Apr)
40.^Kamin W, Ilyenko LI, Malek FA, Kieser MTreatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescentsPediatr Int.(2012 Apr)
42.^Mackinnon LT, Hooper SMucosal (secretory) immune system responses to exercise of varying intensity and during overtrainingInt J Sports Med.(1994 Oct)
43.^Pal M, Febbraio MA, Whitham MFrom cytokine to myokine: the emerging role of interleukin-6 in metabolic regulationImmunol Cell Biol.(2014 Apr)
44.^Thäle C, Kiderlen AF, Kolodziej HAnti-infective activities of Pelargonium sidoides (EPS® 7630): effects of induced NO production on Leishmania major in infected macrophages and antiviral effects as assessed in a fibroblast-virus protection assayPlanta Med.(2011 May)
45.^Kayser O, Kolodziej H, Kiderlen AFImmunomodulatory principles of Pelargonium sidoidesPhytother Res.(2001 Mar)
46.^Trun W, Kiderlen AF, Kolodziej HNitric oxide synthase and cytokines gene expression analyses in Leishmania-infected RAW 264.7 cells treated with an extract of Pelargonium sidoides (Eps 7630)Phytomedicine.(2006 Sep)
47.^Thäle C, Kiderlen A, Kolodziej HAnti-infective mode of action of EPs 7630 at the molecular levelPlanta Med.(2008 May)
48.^Kim CE, Griffiths WJ, Taylor PWComponents derived from Pelargonium stimulate macrophage killing of Mycobacterium speciesJ Appl Microbiol.(2009 Apr)
49.^Kobayashi SD, Voyich JM, Burlak C, DeLeo FRNeutrophils in the innate immune responseArch Immunol Ther Exp (Warsz).(2005 Nov-Dec)
50.^Conrad A, Hansmann C, Engels I, Daschner FD, Frank UExtract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitroPhytomedicine.(2007)
51.^Fashner J, Ericson K, Werner STreatment of the common cold in children and adultsAm Fam Physician.(2012 Jul 15)
52.^Labuschagné A, Hussein AA, Rodríguez B, Lall NSynergistic Antimycobacterial Actions of Knowltonia vesicatoria (L.f) SimsEvid Based Complement Alternat Med.(2012)
53.^Conrad A, Jung I, Tioua D, Lallemand C, Carrapatoso F, Engels I, Daschner FD, Frank UExtract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitroPhytomedicine.(2007)
54.^Janecki A, Conrad A, Engels I, Frank U, Kolodziej HEvaluation of an aqueous-ethanolic extract from Pelargonium sidoides (EPs® 7630) for its activity against group A-streptococci adhesion to human HEp-2 epithelial cellsJ Ethnopharmacol.(2011 Jan 7)
56.^Procyanidins from medicinal birch: bonding patterns and sequence of units in triflavanoids of mixed stereochemistry.()
58.^Sethman CR, Doyle RJ, Cowan MMFlow cytometric evaluation of adhesion of Streptococcus pyogenes to epithelial cellsJ Microbiol Methods.(2002 Sep)
59.^Keles S, Artac H, Kara R, Gokturk B, Ozen A, Reisli ITransient hypogammaglobulinemia and unclassified hypogammaglobulinemia: 'similarities and differences'Pediatr Allergy Immunol.(2010 Aug)
60.^Bachert C, Schapowal A, Funk P, Kieser MTreatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trialRhinology.(2009 Mar)
61.^Michaelis M, Doerr HW, Cinatl J JrInvestigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory virusesPhytomedicine.(2011 Mar 15)
63.^Schnitzler P, Schneider S, Stintzing FC, Carle R, Reichling JEfficacy of an aqueous Pelargonium sidoides extract against herpesvirusPhytomedicine.(2008 Dec)
64.^Wittschier N, Lengsfeld C, Vorthems S, Stratmann U, Ernst JF, Verspohl EJ, Hensel ALarge molecules as anti-adhesive compounds against pathogensJ Pharm Pharmacol.(2007 Jun)
65.^Wittschier N, Faller G, Hensel AAn extract of Pelargonium sidoides (EPs 7630) inhibits in situ adhesion of Helicobacter pylori to human stomachPhytomedicine.(2007 Apr)
66.^Beil W, Kilian PEPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cellsPhytomedicine.(2007)
68.^Flaherty KR, Saint S, Fendrick AM, Martinez FJThe spectrum of acute bronchitis. Using baseline factors to guide empirical therapyPostgrad Med.(2001 Feb)
70.^Slusarcick AL, McCaig LFNational Hospital Ambulatory Medical Care Survey: 1998 outpatient department summaryAdv Data.(2000 Jul 27)
71.^Smucny J, Fahey T, Becker L, Glazier R, McIsaac WAntibiotics for acute bronchitisCochrane Database Syst Rev.(2000)
72.^Matthys H, Kamin WPositioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studiesCurr Med Res Opin.(2013 Oct)
73.^Agbabiaka TB, Guo R, Ernst EPelargonium sidoides for acute bronchitis: a systematic review and meta-analysisPhytomedicine.(2008 May)
74.^Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med.(2007 Sep 15)
75.^Jones PW, Quirk FH, Baveystock CM, Littlejohns PA self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory QuestionnaireAm Rev Respir Dis.(1992 Jun)
76.^Teschke R, Frenzel C, Schulze J, Eickhoff ASpontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertainedRegul Toxicol Pharmacol.(2012 Jun)
77.^Teschke R, Frenzel C, Wolff A, Herzog J, Glass X, Schulze J, Eickhoff A Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvementAnn Hepatol.(2012 Jul-Aug)
78.^de Boer HJ, Hagemann U, Bate J, Meyboom RHAllergic reactions to medicines derived from Pelargonium speciesDrug Saf.(2007)
Primary Use